RT Journal Article
SR Electronic
T1 Optimal design for phase 2 studies of SARS-CoV-2 antiviral drugs
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.06.21249368
DO 10.1101/2021.01.06.21249368
A1 James A Watson
A1 Stephen Kissler
A1 Nicholas PJ Day
A1 Yonatan Grad
A1 Nicholas J White
YR 2021
UL http://medrxiv.org/content/early/2021/03/15/2021.01.06.21249368.abstract
AB There is no agreed methodology for pharmacometric assessment of candidate SARS-CoV-2 antiviral drugs. The most widely used measure of virological response in clinical trials to date is the time to viral clearance assessed by serial qPCR. We posited that rate of viral clearance would have better discriminatory value. Using a pharmacodynamic model fit to individual SARS-CoV-2 qPCR data from 46 prospectively followed uncomplicated COVID-19 infections, we simulated viral load data and showed that rate of viral clearance is a uniformly superior endpoint as compared to time to clearance with respect to type 2 error. Rate of clearance is not dependent on initial viral load or assay sensitivity. We apply our approach to data from a randomised controlled trial of ivermectin. Pharmacometric antiviral assessments should be conducted in early illness with serial qPCR samples taken over one week. Response-adaptive trials using rate of clearance can identify promising antiviral interventions rapidly.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWellcome Trust Grant 093956/Z/10/CAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable: we used de-identified open access data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code are available on the github repositories linked to this manuscript. https://github.com/gradlab/CtTrajectories https://github.com/jwatowatson/phase2sims